CGMs & Non-Insulin-Treated T2D, Islet Autoantibody Screening & T1D, Semaglutide CVD Risk Reduction, and more!Diabetes Core UpdateWelcome to the latest episode (November 2026) of DOC Updates, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disea...5 days agoCGMs & Non-Insulin-Treated T2D, Islet Autoantibody Screening & T1D, Semaglutide CVD Risk Reduction, and more!Diabetes Core Update0:00 / 0:00Read the original at diabetescoreupdate.libsyn.comUse this feed in your RSS readerCopy the publisher’s public feed URL, or build an OPML reading list for another reader.Copy RSS URL Open RSS feed · Find feeds & export OPMLKeep up with this sourceFollow this sourceKeep this source in your dashboard and return to its latest articles. Email alerts are managed separately in Settings.FetchFeeds groups articles by feed so you can follow sources, compare coverage, and save stories for later.Back to all articles from Diabetes Core UpdateMore from this feedChoose another story from Diabetes Core Update.What's Next—Amylin-based TherapiesHypertension Part I—Overview and ManagementHypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of AldosteroneBeyond Diabetes and Obesity: Expanding Applications of Incretin BiologyHypertension Part 3—Advanced Hypertension Management: Challenging CasesVariability in Autoantibody Ordering Patterns & Diabetes Misclassification and Determinants of Cognitive Change Over 1 Year in Older Adults With T1DT2D & Bone Density, Microarchitecture, & Strength; Early Weight Loss, Glucose Tolerance, & Long-Term Mortality/CVD Risk; and more!Sarcopenic Obesity & T2D, Cumulative BMI Burden From Childhood to Adulthood & Risk of Metabolic Multimorbidity, and more!